Literature DB >> 25550921

miR-132/212 cluster inhibits the growth of lung cancer xenografts in nude mice.

Judong Luo1, Cuicui Meng1, Yiting Tang1, Shuyu Zhang2, Meizhen Wan3, Yanzhi Bi4, Xifa Zhou1.   

Abstract

OBJECTIVE: Lung cancer remains the leading cause of cancer-related death worldwide and microRNAs (miRNAs) play important roles in lung cancer progression. In this study, we investigate the effects of miR-132/212 cluster on the growth of subcutaneous xenografts of human lung cancer H1299 cells in nude mice, and further explore the underlying mechanisms.
METHODS: Nude mice with subcutaneous transplantation tumor of human lung cancer H1299 cells were randomly divided into three groups: the sham group, the control vector group, and the microRNA-132/212 group. The control vector and microRNA-132/212 cluster plasmid was intratumoral injected respectively. Tumor volume was measured during the intervention process, with a tumor growth curve generated. Immunohistochemistry was performed to analyze the expression level of Ki-67, P21, CyclinD1 and CD31 in each group.
RESULTS: The tumor volume of miR-132/212 group was significantly smaller than that of the control group at the terminal time point (P < 0.05). The expression levels of Ki-67, CyclinD1 and CD31 in the miR-132/212 group was significantly lower than the control group (P < 0.05), while the expression levels of P21 in the miR-132/212 group were significantly higher than the control group (P < 0.05).
CONCLUSION: miR-132/212 cluster significantly inhibited the growth of subcutaneous xenografts of human lung cancer H1299 cells in nude mice. The inhibitory effect of miR-132/212 cluster in tumor growth may be mediated by upregulating the expression of P21 and downregulating the expression of CyclinD1, thereby inhibiting tumor tissue proliferation and angiogenesis and resulting in the inhibition of tumor growth.

Entities:  

Keywords:  CyclinD1; Lung cancer; P21; angiogenesis; miR-132/212 cluster

Year:  2014        PMID: 25550921      PMCID: PMC4276179     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  32 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

2.  MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.

Authors:  Zhumei Shi; Qiudan Chen; Chongyong Li; Lin Wang; Xu Qian; Chengfei Jiang; Xue Liu; Xiefeng Wang; Hai Li; Chunsheng Kang; Tao Jiang; Ling-Zhi Liu; Yongping You; Ning Liu; Bing-Hua Jiang
Journal:  Neuro Oncol       Date:  2014-05-25       Impact factor: 12.300

3.  Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development.

Authors:  Shuyu Zhang; Jun Hao; Fang Xie; Xiangui Hu; Cong Liu; Jian Tong; Jundong Zhou; Jinchang Wu; Chenghao Shao
Journal:  Carcinogenesis       Date:  2011-06-10       Impact factor: 4.944

4.  miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor.

Authors:  Jong-Kook Park; Jon C Henry; Jinmai Jiang; Christine Esau; Yuriy Gusev; Megan R Lerner; Russell G Postier; Daniel J Brackett; Thomas D Schmittgen
Journal:  Biochem Biophys Res Commun       Date:  2011-02-15       Impact factor: 3.575

Review 5.  DNA methylation and cancer pathways in gastrointestinal tumors.

Authors:  Hiromu Suzuki; Takashi Tokino; Yasuhisa Shinomura; Kohzoh Imai; Minoru Toyota
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

6.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.

Authors:  Li Ma; Julie Teruya-Feldstein; Robert A Weinberg
Journal:  Nature       Date:  2007-09-26       Impact factor: 49.962

7.  Upregulation of Ying Yang 1 (YY1) suppresses esophageal squamous cell carcinoma development through heme oxygenase-1.

Authors:  Judong Luo; Xifa Zhou; Xin Ge; Pengfei Liu; Jianping Cao; Xujing Lu; Yang Ling; Shuyu Zhang
Journal:  Cancer Sci       Date:  2013-09-05       Impact factor: 6.716

8.  NF-kappaB P50/P65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop.

Authors:  Jiayi Wang; Zhidong Gu; Peihua Ni; Yongxia Qiao; Changqiang Chen; Xiangfan Liu; Jiafei Lin; Ning Chen; Qishi Fan
Journal:  Nucleic Acids Res       Date:  2011-05-13       Impact factor: 16.971

9.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

10.  miR-7 inhibits colorectal cancer cell proliferation and induces apoptosis by targeting XRCC2.

Authors:  Kaiwu Xu; Zhihui Chen; Changjiang Qin; Xinming Song
Journal:  Onco Targets Ther       Date:  2014-02-20       Impact factor: 4.147

View more
  11 in total

1.  Human thymic stromal lymphopoietin promotes the proliferation and invasion of cervical cancer cells by downregulating microRNA-132 expression.

Authors:  Wen-Jie Zhou; Hui-Li Yang; Kai-Kai Chang; Yi Meng; Ming-Yan Wang; Min-Min Yuan; Ming-Qing Li; Feng Xie
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

Review 2.  MiRNA-based therapeutic intervention of cancer.

Authors:  Srivatsava Naidu; Peter Magee; Michela Garofalo
Journal:  J Hematol Oncol       Date:  2015-06-11       Impact factor: 17.388

3.  μ Opioid Receptor Expression after Morphine Administration Is Regulated by miR-212/132 Cluster.

Authors:  Adrian Garcia-Concejo; Ada Jimenez-Gonzalez; Raquel E Rodríguez
Journal:  PLoS One       Date:  2016-07-05       Impact factor: 3.240

4.  P53-dependent downregulation of hTERT protein expression and telomerase activity induces senescence in lung cancer cells as a result of pterostilbene treatment.

Authors:  Rong-Jane Chen; Pei-Hsuan Wu; Chi-Tang Ho; Tzong-Der Way; Min-Hsiung Pan; Hsiu-Min Chen; Yuan-Soon Ho; Ying-Jan Wang
Journal:  Cell Death Dis       Date:  2017-08-10       Impact factor: 8.469

5.  Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.

Authors:  Hui-Ming Lin; Kate L Mahon; Calan Spielman; Howard Gurney; Girish Mallesara; Martin R Stockler; Patricia Bastick; Karen Briscoe; Gavin Marx; Alexander Swarbrick; Lisa G Horvath
Journal:  Br J Cancer       Date:  2017-03-09       Impact factor: 7.640

6.  MiR-132/212 promotes the growth of precartilaginous stem cells (PCSCs) by regulating Ihh/PTHrP signaling pathway.

Authors:  Fu-Yong Zhang; Yun-Fang Zhen; Zhi-Xiong Guo; Jin Dai; Lun-Qing Zhu; Xu Cao; Guang-Hao Su; Wen-Yan Zhang; Jian-Feng Fang; Zhen-Hua Zhu; Chun-Hua Yin; Ya Liu; Gao Yu; Tan-Tan Zhao; Ya Zhang; Quan-Wen Yuan; Xiao-Dong Wang
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

Review 7.  microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis.

Authors:  Tiziana Annese; Roberto Tamma; Michelina De Giorgis; Domenico Ribatti
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244

8.  Hsa_circ_0020850 promotes the malignant behaviors of lung adenocarcinoma by regulating miR-326/BECN1 axis.

Authors:  Xiaoju Li; Shengtian Su; Dan Ye; Zhigao Yu; Wenjing Lu; Liang Liu
Journal:  World J Surg Oncol       Date:  2022-01-10       Impact factor: 2.754

9.  miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.

Authors:  Junjie Xiao; Yihua Bei; Jingqi Liu; Jasmina Dimitrova-Shumkovska; Dapeng Kuang; Qiulian Zhou; Jin Li; Yanning Yang; Yang Xiang; Fei Wang; Changqing Yang; Wenzhuo Yang
Journal:  J Cell Mol Med       Date:  2015-12-09       Impact factor: 5.310

Review 10.  Targeting MicroRNAs in Prostate Cancer Radiotherapy.

Authors:  Jie Ni; Joseph Bucci; Lei Chang; David Malouf; Peter Graham; Yong Li
Journal:  Theranostics       Date:  2017-07-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.